BTIG Maintains Their Buy Rating on LifeMD (LFMD)


BTIG analyst David Larsen maintained a Buy rating on LifeMD (LFMD) on June 3 and set a price target of $40.00. The company’s shares closed last Monday at $13.14.

According to TipRanks.com, Larsen is a 2-star analyst with an average return of 1.3% and a 38.5% success rate. Larsen covers the Technology sector, focusing on stocks such as American Well, SOC Telemed, and Accolade.

LifeMD has an analyst consensus of Moderate Buy, with a price target consensus of $37.50.

See today’s analyst top recommended stocks >>

LifeMD’s market cap is currently $343.6M and has a P/E ratio of -2.90. The company has a Price to Book ratio of -486.54.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LFMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Conversion Labs, Inc. engages in the manufacturing, distribution, and sale of natural immune support products containing proprietary yeast beta glucans. Its products are oral intake tablets and topical creams, and gels for skin application. It operates through the Finished Cosmetic Products and Nutraceutical and Cosmetic Additives segments. The company was founded in 1987 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts